NCT05050006Phase 2Terminated

ITIL-168 in Advanced Melanoma

Study sponsor: Instil Bio

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2023-02-27Actual

Enrollment · participants29Actual

Source updated2024-04-16Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Advanced Cutaneous Melanoma

Treatments or interventions studied

ITIL-168Biological

Primary outcomes · main study measures

measure: Objective response rate; description: Objective response rate (ORR), defined as the incidence of a complete response (CR) or a partial response (PR) per a modified Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria, as assessed by central review.; timeFrame: Up to 60 months

History coverage

Imported research includes version dates later than the current official API record (2024-04-16). Disputed observations are retained for audit and excluded from trusted change feeds and sponsor statistics. Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history